Celtaxsys receives FDA approval to begin acebilustat’s trial of CF

Clinical-stage pharmaceutical development firm Celtaxsys has received approval from the US Food and Drug Administration (FDA) to start a Phase II clinical trial of its drug candidate, acebilustat (CTX-4430), in adult cystic fibrosis (CF) patients in …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news